文献速递心律失常

流出道室早消融中追加消融灶的随机临床试验

Additional Lesion Sets in Ablation of Outflow Tract Premature Ventricular Contractions: A Randomized Clinical Trial.
PubMed 文献 · JAMA Cardiol · 2024-01-01

这项多中心随机临床试验纳入308例首次接受流出道室早消融的患者,在单点消融消除室早后随机分为追加消融组与对照组。结果显示追加消融组3个月无复发率显著高于对照组(97.9% vs 82.7%,P<.001),且无严重围术期并发症。

要点

  • 单点消融有效后追加周围消融灶可显著降低流出道室早复发率。
  • 追加消融组3个月无复发率97.9%,对照组82.7%,差异有统计学意义。
  • 两组均无严重围术期并发症,追加消融未增加并发症风险。

核心结论

  • 在流出道室早消融中,于索引有效消融点周围追加消融灶较单点消融可降低复发率,且不增加并发症风险。

研究设计与样本

  • 多中心、前瞻性、随机临床试验,自中国18家医院纳入2021年10月至2023年2月首次接受流出道室早导管消融的患者。
  • 308例患者入组,286例随机(平均年龄49.2岁,女性173例占60.5%),随机分为追加消融组或对照组,计划术后随访3个月。

主要发现

  • 追加消融组平均射频应用6.3次,对照组平均1次。
  • 中位随访3.2个月,追加消融组无复发率97.9%(139/142),对照组82.7%(115/139),P<.001。
  • 追加消融组室早负荷平均降低23.0%,对照组19.0%,P=.002。
  • 两组均无严重围术期并发症。

关键数值与推荐

  • 主要终点为从基线至术后3个月无室早复发,定义为室早负荷减少≥80%(24小时室早数/24小时总心搏数×100%)。

临床怎么用

  • 在流出道室早消融中,单点消融消除室早后,可考虑在索引有效消融点周围追加消融以降低复发。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Recurrence remains a challenge after ablation of outflow tract premature ventricular contractions (OT-PVCs). Although adding additional lesions next to the index effective ablation site is sometimes performed to reinforce the ablation, it remains uncertain whether this approach is effective. OBJECTIVE: To test the hypothesis that additional ablation lesions would reduce the recurrence rate compared with single-point ablation at the index effective site for the ablation of OT-PVCs. DESIGN, SETTING, AND PARTICIPANTS: This study was a multicenter, prospective, randomized clinical trial. Patients receiving their first catheter ablation for OT-PVCs were enrolled from 18 hospitals in China between October 2021 and February 2023. Scheduled follow-up duration was 3 months after the procedure. INTERVENTION: After identifying the target point and eliminating the PVC by a single-point ablation, patients were randomized 1:1 into an additional ablation group or a control group. MAIN OUTCOMES AND MEASURES: The primary end point of the study was freedom from PVC recurrence (≥80% reduction of PVC burden, which is the number of PVCs in 24 hours/total heartbeats in 24 hours × 100%) from baseline to 3 months postprocedure. RESULTS: Of 308 patients enrolled in the study, 286 (mean [SD] age, 49.2 [14.6] years; 173 female [60.5%]) were randomized to the additional ablation or the control group. The additional ablation group had a mean (SD) of 6.3 (1.1) radiofrequency applications, whereas the control group (single-point ablation group) had a mean (SD) of 1 (0) radiofrequency application. After a median (IQR) follow-up of 3.2 (0) months, the rate of freedom from PVCs was significantly higher in the additional ablation group (139 of 142 [97.9%]) compared with the control group (115 of 139 [82.7%]; P < .001). Patients in the additional ablation group also had a more substantial reduction in PVC burden than the control group (mean [SD] reduction, 23.0% [10.5%] vs 19.0% [10.4%]; P = .002). There were no severe periprocedural complications in either group. CONCLUSIONS AND RELEVANCE: This randomized clinical trial showed a benefit of additional ablation in reducing the recurrence of OT-PVCs compared with the single-point ablation strategy, without increased complication risk. Additional ablations surrounding the index effective ablation point should be considered in OT-PVC ablation. TRIAL REGISTRATION: Chinese Clinical Trials Registry Identifier: ChiCTR2200055340.

来源:JAMA Cardiol,查看原文。版权归原作者所有。

引用

  1. Wang K, Yi F, Xiao F, et al. Additional Lesion Sets in Ablation of Outflow Tract Premature Ventricular Contractions: A Randomized Clinical Trial. JAMA Cardiol. 2024. PMID: 39320873. doi:10.1001/jamacardio.2024.2975

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。